|
2020-12-11 |
2020-12-09 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
2 793
-49.7%
79,69
222 574 USD
|
2 793
-49.7%
|
79,69
|
222 574 USD
|
|
|
2020-11-17 |
2020-11-16 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
7 603
-57.5%
86,57
658 192 USD
|
7 603
-57.5%
|
86,57
|
658 192 USD
|
|
|
2020-11-17 |
2020-11-13 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
13 282
-70.3%
83,82
1 113 318 USD
|
13 282
-70.3%
|
83,82
|
1 113 318 USD
|
|
|
2020-11-12 |
2020-11-10 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
6 000
-51.6%
81,57
489 420 USD
|
6 000
-51.6%
|
81,57
|
489 420 USD
|
|
|
2020-11-06 |
2020-11-05 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
3 589
-39.0%
79,87
286 653 USD
|
3 589
-39.0%
|
79,87
|
286 653 USD
|
|
|
2020-11-06 |
2020-11-04 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
3 434
-37.9%
79,89
274 351 USD
|
3 434
-37.9%
|
79,89
|
274 351 USD
|
|
|
2020-11-06 |
2020-11-04 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
139
-0.6%
80,00
11 120 USD
|
139
-0.6%
|
80,00
|
11 120 USD
|
|
|
2020-11-06 |
2020-11-04 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
2 481
-9.7%
80,00
198 481 USD
|
2 481
-9.7%
|
80,00
|
198 481 USD
|
|
|
2020-10-20 |
2020-10-16 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
183
-3.2%
79,87
14 616 USD
|
183
-3.2%
|
79,87
|
14 616 USD
|
|
|
2020-10-07 |
2020-10-07 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
1 500
-6.1%
78,50
117 753 USD
|
1 500
-6.1%
|
78,50
|
117 753 USD
|
|
|
2020-10-07 |
2020-10-06 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
4 778
-17.2%
78,50
375 094 USD
|
4 778
-17.2%
|
78,50
|
375 094 USD
|
|
|
2020-10-07 |
2020-10-05 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
14 637
-38.9%
78,51
1 149 110 USD
|
14 637
-38.9%
|
78,51
|
1 149 110 USD
|
|
|
2020-06-10 |
2020-06-08 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
1 415
-5.8%
78,50
111 078 USD
|
1 415
-5.8%
|
78,50
|
111 078 USD
|
|
|
2020-05-19 |
2020-05-15 |
A
Achat
|
MURRAY JAMES E
President and COO
Dirigeant
|
4 500
+inf%
67,63
304 317 USD
|
4 500
+inf%
|
67,63
|
304 317 USD
|
|
|
2020-01-03 |
2020-01-02 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
200
-1.0%
78,53
15 706 USD
|
200
-1.0%
|
78,53
|
15 706 USD
|
|
|
2019-12-31 |
2019-12-30 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
104
-0.5%
78,50
8 164 USD
|
104
-0.5%
|
78,50
|
8 164 USD
|
|
|
2019-12-30 |
2019-12-27 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
606
-2.9%
78,54
47 597 USD
|
606
-2.9%
|
78,54
|
47 597 USD
|
|
|
2019-12-27 |
2019-12-26 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
1 923
-8.7%
78,52
150 987 USD
|
1 923
-8.7%
|
78,52
|
150 987 USD
|
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
6 114
-23.3%
78,54
480 166 USD
|
6 114
-23.3%
|
78,54
|
480 166 USD
|
|
|
2019-12-17 |
2019-12-16 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
5 735
-22.1%
78,62
450 886 USD
|
5 735
-22.1%
|
78,62
|
450 886 USD
|
|
|
2019-12-11 |
2019-12-09 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
16 766
-85.7%
78,72
1 319 742 USD
|
16 766
-85.7%
|
78,72
|
1 319 742 USD
|
|
|
2018-07-03 |
2018-07-02 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-30.5%
95,86
1 282 061 USD
|
13 375
-30.5%
|
95,86
|
1 282 061 USD
|
|
|
2018-06-04 |
2018-06-01 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-30.5%
92,21
1 233 326 USD
|
13 375
-30.5%
|
92,21
|
1 233 326 USD
|
|
|
2018-05-02 |
2018-05-01 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-23.2%
86,02
1 150 576 USD
|
13 375
-23.2%
|
86,02
|
1 150 576 USD
|
|
|
2018-04-04 |
2018-04-02 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
Dirigeant
|
1 666
-100.0%
106,20
176 929 USD
|
1 666
-100.0%
|
106,20
|
176 929 USD
|
|
|
2018-04-04 |
2018-04-02 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-23.2%
103,52
1 384 583 USD
|
13 375
-23.2%
|
103,52
|
1 384 583 USD
|
|
|
2018-03-06 |
2018-03-05 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
15 428
-100.0%
99,04
1 527 968 USD
|
15 428
-100.0%
|
99,04
|
1 527 968 USD
|
|
|
2018-03-06 |
2018-03-05 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
22 875
-63.0%
99,05
2 265 698 USD
|
22 875
-63.0%
|
99,05
|
2 265 698 USD
|
|
|
2018-03-02 |
2018-03-01 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-31.2%
101,20
1 353 497 USD
|
13 375
-31.2%
|
101,20
|
1 353 497 USD
|
|
|
2018-02-02 |
2018-02-01 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 375
-31.2%
99,20
1 326 765 USD
|
13 375
-31.2%
|
99,20
|
1 326 765 USD
|
|
|
2018-01-04 |
2018-01-03 |
V
Vente
|
Rubin Jonathan N
Chief Financial Officer
Dirigeant
|
30 086
-53.2%
96,16
2 893 028 USD
|
30 086
-53.2%
|
96,16
|
2 893 028 USD
|
|
|
2018-01-03 |
2018-01-02 |
V
Vente
|
SMITH BARRY M
Chief Executive Officer
Administrateur exécutif
|
13 367
-31.2%
95,94
1 282 429 USD
|
13 367
-31.2%
|
95,94
|
1 282 429 USD
|
|
|
2018-01-03 |
2018-01-02 |
V
Vente
|
Rubin Jonathan N
Chief Financial Officer
Dirigeant
|
17 443
-39.7%
96,07
1 675 782 USD
|
17 443
-39.7%
|
96,07
|
1 675 782 USD
|
|
|
2017-12-06 |
2017-12-04 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
2 180
-100.0%
92,00
200 560 USD
|
2 180
-100.0%
|
92,00
|
200 560 USD
|
|
|
2017-12-05 |
2017-12-04 |
V
Vente
|
Lewis Clapper Caskie
Chief Human Resources Officer
|
59 313
-76.3%
93,99
5 574 586 USD
|
59 313
-76.3%
|
93,99
|
5 574 586 USD
|
|
|
2017-12-04 |
2017-12-01 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
8 275
-38.1%
89,08
737 137 USD
|
8 275
-38.1%
|
89,08
|
737 137 USD
|
|
|
2017-11-02 |
2017-11-01 |
VP
Vente planifiée
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
9 369
-41.0%
89,20
835 751 USD
|
9 369
-41.0%
|
89,20
|
835 751 USD
|
|
|
2017-11-02 |
2017-11-01 |
VP
Vente planifiée
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 154
-100.0%
92,00
106 168 USD
|
1 154
-100.0%
|
92,00
|
106 168 USD
|
|
|
2017-10-05 |
2017-10-04 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
2 475
-15.5%
88,10
218 048 USD
|
2 475
-15.5%
|
88,10
|
218 048 USD
|
|
|
2017-10-05 |
2017-10-04 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
5 000
-23.9%
88,00
440 000 USD
|
5 000
-23.9%
|
88,00
|
440 000 USD
|
|
|
2017-10-05 |
2017-10-03 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
5 000
-27.1%
88,00
440 000 USD
|
5 000
-27.1%
|
88,00
|
440 000 USD
|
|
|
2017-10-04 |
2017-10-03 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
30 021
-68.3%
87,31
2 621 242 USD
|
30 021
-68.3%
|
87,31
|
2 621 242 USD
|
|
|
2017-10-03 |
2017-10-02 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
19 007
-57.7%
86,22
1 638 689 USD
|
19 007
-57.7%
|
86,22
|
1 638 689 USD
|
|
|
2017-10-03 |
2017-09-29 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
18 511
-57.1%
86,18
1 595 317 USD
|
18 511
-57.1%
|
86,18
|
1 595 317 USD
|
|
|
2017-09-29 |
2017-09-28 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
4 848
-100.0%
85,76
415 782 USD
|
4 848
-100.0%
|
85,76
|
415 782 USD
|
|
|
2017-09-29 |
2017-09-28 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
25 316
-64.5%
85,85
2 173 452 USD
|
25 316
-64.5%
|
85,85
|
2 173 452 USD
|
|
|
2017-09-29 |
2017-09-27 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
1 419
-9.2%
86,06
122 125 USD
|
1 419
-9.2%
|
86,06
|
122 125 USD
|
|
|
2017-09-29 |
2017-09-27 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
|
18 502
-54.7%
85,24
1 577 131 USD
|
18 502
-54.7%
|
85,24
|
1 577 131 USD
|
|
|
2017-09-28 |
2017-09-27 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
35 658
-72.6%
85,17
3 036 928 USD
|
35 658
-72.6%
|
85,17
|
3 036 928 USD
|
|
|
2017-09-28 |
2017-09-27 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
600
-100.0%
86,06
51 635 USD
|
600
-100.0%
|
86,06
|
51 635 USD
|
|
|
2017-09-28 |
2017-09-27 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
18 526
-96.9%
85,31
1 580 373 USD
|
18 526
-96.9%
|
85,31
|
1 580 373 USD
|
|
|
2017-09-18 |
2017-09-15 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
2 402
-15.1%
83,00
199 366 USD
|
2 402
-15.1%
|
83,00
|
199 366 USD
|
|
|
2017-09-18 |
2017-09-15 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
2 961
-100.0%
84,00
248 724 USD
|
2 961
-100.0%
|
84,00
|
248 724 USD
|
|
|
2017-09-18 |
2017-09-14 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
18 063
-57.3%
83,05
1 500 163 USD
|
18 063
-57.3%
|
83,05
|
1 500 163 USD
|
|
|
2017-09-14 |
2017-09-13 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
585
-100.0%
83,00
48 555 USD
|
585
-100.0%
|
83,00
|
48 555 USD
|
|
|
2017-09-14 |
2017-09-13 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
14 096
-51.2%
83,06
1 170 883 USD
|
14 096
-51.2%
|
83,06
|
1 170 883 USD
|
|
|
2017-09-14 |
2017-09-12 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
19
-100.0%
83,00
1 577 USD
|
19
-100.0%
|
83,00
|
1 577 USD
|
|
|
2017-09-12 |
2017-09-11 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
670
-100.0%
83,00
55 610 USD
|
670
-100.0%
|
83,00
|
55 610 USD
|
|
|
2017-09-12 |
2017-09-11 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
2 400
-15.1%
83,00
199 200 USD
|
2 400
-15.1%
|
83,00
|
199 200 USD
|
|
|
2017-09-11 |
2017-09-08 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
6 267
-100.0%
81,53
510 918 USD
|
6 267
-100.0%
|
81,53
|
510 918 USD
|
|
|
2017-09-08 |
2017-09-07 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 033
-100.0%
81,19
83 870 USD
|
1 033
-100.0%
|
81,19
|
83 870 USD
|
|
|
2017-09-08 |
2017-09-05 |
V
Vente
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 157
-100.0%
80,96
93 669 USD
|
1 157
-100.0%
|
80,96
|
93 669 USD
|
|
|
2017-07-26 |
2017-07-25 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
4 559
-25.3%
80,68
367 820 USD
|
4 559
-25.3%
|
80,68
|
367 820 USD
|
|
|
2017-07-25 |
2017-07-24 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
32 398
-70.7%
80,12
2 595 582 USD
|
32 398
-70.7%
|
80,12
|
2 595 582 USD
|
|
|
2017-07-25 |
2017-07-21 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
1 176
-8.0%
80,02
94 102 USD
|
1 176
-8.0%
|
80,02
|
94 102 USD
|
|
|
2017-07-21 |
2017-07-20 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
16 073
-54.4%
80,06
1 286 751 USD
|
16 073
-54.4%
|
80,06
|
1 286 751 USD
|
|
|
2017-07-21 |
2017-07-20 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
1 109
-7.4%
80,01
88 728 USD
|
1 109
-7.4%
|
80,01
|
88 728 USD
|
|
|
2017-07-18 |
2017-07-17 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
600
-4.1%
80,10
48 060 USD
|
600
-4.1%
|
80,10
|
48 060 USD
|
|
|
2017-07-18 |
2017-07-14 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
27 914
-66.7%
80,07
2 234 940 USD
|
27 914
-66.7%
|
80,07
|
2 234 940 USD
|
|
|
2017-07-17 |
2017-07-14 |
V
Vente
|
GREGOIRE DANIEL N
General Counsel and Secretary
Dirigeant
|
14 114
-51.2%
80,11
1 130 685 USD
|
14 114
-51.2%
|
80,11
|
1 130 685 USD
|
|
|
2017-02-27 |
2017-02-24 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
100
-0.9%
82,10
8 210 USD
|
100
-0.9%
|
82,10
|
8 210 USD
|
|
|
2017-02-27 |
2017-02-24 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
100
-0.9%
81,05
8 105 USD
|
100
-0.9%
|
81,05
|
8 105 USD
|
|
|
2017-02-27 |
2017-02-24 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
100
-0.9%
80,00
8 000 USD
|
100
-0.9%
|
80,00
|
8 000 USD
|
|
|
2017-02-27 |
2017-02-23 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
300
-2.5%
81,12
24 335 USD
|
300
-2.5%
|
81,12
|
24 335 USD
|
|
|
2017-02-27 |
2017-02-23 |
V
Vente
|
WEST JEFFREY N
SVP & Controller
Dirigeant
|
12 912
-51.9%
80,28
1 036 516 USD
|
12 912
-51.9%
|
80,28
|
1 036 516 USD
|
|
